Moderna expands the field of mrna medicine with positive clinical results across cancer, rare disease, and infectious disease
Company's flu vaccine, mrna-1010, met its primary endpoint in phase 3 trial; separate phase 1/2 data demonstrated higher hai titers than fluzone hd vaccine pipeline advancing rapidly with company announcing the completion of rsv bla filing (mrna-1345), completion of adult enrollment in the phase 3 trial of mrna-1647, a first-in-class vaccine against cmv, and the phase 3 trial of mrna-1283, a next-generation covid-19 vaccine with its partner merck, the company plans to begin a second phase 3 trial of mrna-4157, its individualized neoantigen therapy (int), in combination with keytruda®, for non-small cell lung cancer later this year; updated efficacy follow-up from the ongoing phase 2 study in adjuvant melanoma expected in q4 with positive clinical data announced in mrna-3705, a treatment for methylmalonic acidemia, the company has three chronic rare disease medicines that have demonstrated potential for clinical benefit in patients over the next five years, the company expects to launch up to 15 new products addressing high unmet needs, to bring up to 50 new candidates into clinical trials and to continue expanding the field of mrna into new applications cambridge, ma / accesswire / september 13, 2023 / moderna, inc. (nasdaq:mrna) today announced business and clinical updates across its franchises and introduced several new development programs at the company's annual r&d day. "our mrna platform is working.
MRNA Ratings Summary
MRNA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission